Medpace Holdings, Inc. (MEDP) Total Return:53.47%(TTM)
Over the latest trailing 12-month period, Medpace Holdings, Inc. (MEDP)'s total return cagr is +53.47%. The comparable SPY value is +26.54%. Year-to-date total return is -18.62%. Total return includes price appreciation and reinvested dividends.
Growth of $10,000 in MEDP
$164,480
(16.4x return)
Invested on Aug 11, 2016
Growth of $10,000 in SPY (S&P 500)
$39,752
(4.0x return)
Invested on Aug 11, 2016
Hypothetical Growth of $10,000
This chart illustrates the cumulative performance of a hypothetical $10,000 investment. It assumes that all dividends paid by both the stock and SPY are reinvested in additional shares on the payment date, showing the true long-term compounding impact of distributions.
Recent Performance Indicators
YTD Total Return
-18.6%
1-Year Total Return
+53.4%
Current Dividend Yield
0.00%
Price CAGR vs. Total Return CAGR
Compound Annual Growth Rate (CAGR) is shown below. The difference between price CAGR and total return CAGR is the compound contribution of dividends reinvested.
| Holding Period | Price CAGR | Total Return CAGR | Dividend Addition |
|---|---|---|---|
| 1 Year | +53.5% | +53.5% | — |
| 3 Years | +27.2% | +27.2% | — |
| 5 Years | +20.3% | +20.3% | — |
| 10 Years | — | — | — |
| 15 Years | — | — | — |
| 20 Years | — | — | — |
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle